Free Trial

GAMMA Investing LLC Purchases 37,735 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amphastar Pharmaceuticals logo with Medical background

GAMMA Investing LLC increased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 4,151.3% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,644 shares of the company's stock after acquiring an additional 37,735 shares during the quarter. GAMMA Investing LLC owned about 0.08% of Amphastar Pharmaceuticals worth $1,120,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in the stock. Boston Partners purchased a new position in shares of Amphastar Pharmaceuticals during the fourth quarter valued at about $15,778,000. Wealthfront Advisers LLC purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth about $9,268,000. Systematic Financial Management LP bought a new stake in Amphastar Pharmaceuticals during the 4th quarter valued at approximately $9,147,000. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after acquiring an additional 105,288 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 402.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 118,851 shares of the company's stock worth $4,413,000 after acquiring an additional 95,192 shares during the period. Institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Down 1.1%

AMPH stock traded down $0.27 on Thursday, reaching $25.34. 393,981 shares of the company traded hands, compared to its average volume of 490,302. The firm has a fifty day simple moving average of $24.72 and a 200-day simple moving average of $30.56. The company has a market cap of $1.19 billion, a P/E ratio of 9.18, a price-to-earnings-growth ratio of 6.67 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a one year low of $22.64 and a one year high of $53.96. The company has a debt-to-equity ratio of 0.80, a current ratio of 2.95 and a quick ratio of 2.02.

Analyst Upgrades and Downgrades

AMPH has been the subject of a number of research analyst reports. Wells Fargo & Company lowered their target price on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Piper Sandler lowered their price objective on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has a consensus rating of "Hold" and a consensus price target of $32.33.

Get Our Latest Report on Amphastar Pharmaceuticals

Amphastar Pharmaceuticals Profile

(Free Report)

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

Further Reading

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Should You Invest $1,000 in Amphastar Pharmaceuticals Right Now?

Before you consider Amphastar Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.

While Amphastar Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines